About Epcoritamab
            
            Class: | Monoclonal antibody (anti-CD3 and anti-CD20)  
Use: | Treatment of adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)  
Adult dose: | Initial dose of 1 mg administered subcutaneously, followed by a step-up dosing schedule to 60 mg; maintenance dose of 60 mg administered subcutaneously every 4 weeks  
Pediatric dose: | Safety and efficacy not established in pediatric patients  
Side effects: | Cytokine release syndrome, infusion-related reactions, fatigue, nause
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (anti-CD3 and anti-CD20)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: AbbVie Deutschland GmbH & Co. KG [Ludwigshafen;Germany], Germany
                    
                    
                    Package Size
                    1 Glass Vial (0.8 mL)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 40898.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose of 1 mg administered subcutaneously, followed by a step-up dosing schedule to 60 mg; maintenance dose of 60 mg administered subcutaneously every 4 weeks
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Cytokine release syndrome, infusion-related reactions, fatigue, nausea, headache, rash, and increased risk of infections
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to epcoritamab or any component of the formulation; active infections
         
        
        
            
                Important Warnings
            
            Monitor for signs of cytokine release syndrome; may cause severe or life-threatening infections; caution in patients with a history of autoimmune disease or prior malignancies
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.